Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Role of (myo)fibroblasts in the development of vascular and connective tissue structure of the C38 colorectal cancer in mice.

Bugyik E, Szabó V, Dezső K, Rókusz A, Szücs A, Nagy P, Tóvári J, László V, Döme B, Paku S.

Cancer Commun (Lond). 2018 Jul 5;38(1):46. doi: 10.1186/s40880-018-0316-x.

2.

Afatinib restrains K-RAS-driven lung tumorigenesis.

Moll HP, Pranz K, Musteanu M, Grabner B, Hruschka N, Mohrherr J, Aigner P, Stiedl P, Brcic L, Laszlo V, Schramek D, Moriggl R, Eferl R, Moldvay J, Dezso K, Lopez-Casas PP, Stoiber D, Hidalgo M, Penninger J, Sibilia M, Győrffy B, Barbacid M, Dome B, Popper H, Casanova E.

Sci Transl Med. 2018 Jun 20;10(446). pii: eaao2301. doi: 10.1126/scitranslmed.aao2301.

PMID:
29925635
3.

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.

Molnár E, Rittler D, Baranyi M, Grusch M, Berger W, Döme B, Tóvári J, Aigner C, Tímár J, Garay T, Hegedűs B.

BMC Cancer. 2018 May 8;18(1):542. doi: 10.1186/s12885-018-4455-x.

4.

Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo.

Laszlo V, Valko Z, Kovacs I, Ozsvar J, Hoda MA, Klikovits T, Lakatos D, Czirok A, Garay T, Stiglbauer A, Helbich TH, Gröger M, Tovari J, Klepetko W, Pirker C, Grusch M, Berger W, Hilberg F, Hegedus B, Dome B.

Clin Cancer Res. 2018 May 3. doi: 10.1158/1078-0432.CCR-17-1507. [Epub ahead of print]

PMID:
29724868
5.

Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.

Rojkó L, Reiniger L, Téglási V, Fábián K, Pipek O, Vágvölgyi A, Agócs L, Fillinger J, Kajdácsi Z, Tímár J, Döme B, Szállási Z, Moldvay J.

J Cancer Res Clin Oncol. 2018 Jul;144(7):1219-1226. doi: 10.1007/s00432-018-2642-4. Epub 2018 Apr 19.

PMID:
29675791
6.

FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal.

Schelch K, Wagner C, Hager S, Pirker C, Siess K, Lang E, Lin R, Kirschner MB, Mohr T, Brcic L, Marian B, Holzmann K, Grasl-Kraupp B, Krupitza G, Laszlo V, Klikovits T, Dome B, Hegedus B, Garay T, Reid G, van Zandwijk N, Klepetko W, Berger W, Grusch M, Hoda MA.

Carcinogenesis. 2018 Apr 5;39(4):534-545. doi: 10.1093/carcin/bgy018.

PMID:
29635378
7.

DNA methylation of microRNA-coding genes in non-small-cell lung cancer patients.

Heller G, Altenberger C, Steiner I, Topakian T, Ziegler B, Tomasich E, Lang G, End-Pfützenreuter A, Zehetmayer S, Döme B, Arns BM, Klepetko W, Zielinski CC, Zöchbauer-Müller S.

J Pathol. 2018 Aug;245(4):387-398. doi: 10.1002/path.5079. Epub 2018 Jun 20.

PMID:
29570800
8.

Reshaping a multimode laser beam into a constructed Gaussian beam for generating a thin light sheet.

Saghafi S, Haghi-Danaloo N, Becker K, Sabdyusheva I, Foroughipour M, Hahn C, Pende M, Wanis M, Bergmann M, Stift J, Hegedus B, Dome B, Dodt HU.

J Biophotonics. 2018 Jun;11(6):e201700213. doi: 10.1002/jbio.201700213. Epub 2018 Mar 24.

PMID:
29457696
9.

Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma.

Klikovits T, Stockhammer P, Laszlo V, Dong Y, Hoda MA, Ghanim B, Opitz I, Frauenfelder T, Nguyen-Kim TDL, Weder W, Berger W, Grusch M, Aigner C, Klepetko W, Dome B, Renyi-Vamos F, Oehler R, Hegedus B.

Sci Rep. 2017 Nov 28;7(1):16456. doi: 10.1038/s41598-017-16551-7.

10.

Intrathoracic solitary fibrous tumor - an international multicenter study on clinical outcome and novel circulating biomarkers.

Ghanim B, Hess S, Bertoglio P, Celik A, Bas A, Oberndorfer F, Melfi F, Mussi A, Klepetko W, Pirker C, Berger W, Harmati I, Farkas A, Jan Ankersmit H, Dome B, Fillinger J, Aigner C, Hegedus B, Renyi-Vamos F, Lang G.

Sci Rep. 2017 Oct 2;7(1):12557. doi: 10.1038/s41598-017-12914-2.

11.

Launching the Hungarian Lung Transplantation Program.

Rényi-Vámos F, Radeczky P, Gieszer B, Ghimessy Á, Czebe K, Török K, Döme B, Elek J, Klepetko W, Lang G, Madurka I.

Transplant Proc. 2017 Sep;49(7):1535-1537. doi: 10.1016/j.transproceed.2017.06.017.

PMID:
28838435
12.

Renal Impairment Hampers Bisphosphonate Treatment in a Quarter of Lung Cancer Patients with Bone Metastasis.

Fábián K, Puskás R, Kakuk T, Prés L, Fejes D, Szegedi Z, Rojkó L, Szállási Z, Döme B, Pipek O, Moldvay J.

Basic Clin Pharmacol Toxicol. 2017 Aug 21. doi: 10.1111/bcpt.12876. [Epub ahead of print]

PMID:
28834230
13.

BARD1 serum autoantibodies for the detection of lung cancer.

Pilyugin M, Descloux P, André PA, Laszlo V, Dome B, Hegedus B, Sardy S, Janes S, Bianco A, Laurent GJ, Irminger-Finger I.

PLoS One. 2017 Aug 7;12(8):e0182356. doi: 10.1371/journal.pone.0182356. eCollection 2017.

14.

Image-Based Chemical Structure Determination.

Ofner J, Brenner F, Wieland K, Eitenberger E, Kirschner J, Eisenmenger-Sittner C, Török S, Döme B, Konegger T, Kasper-Giebl A, Hutter H, Friedbacher G, Lendl B, Lohninger H.

Sci Rep. 2017 Jul 28;7(1):6832. doi: 10.1038/s41598-017-07041-x.

15.

Renal Impairment Hampers Bisphosphonate Treatment in a Quarter of Lung Cancer Patients with Bone Metastasis.

Fábián K, Puskás R, Kakuk T, Prés L, Fejes D, Szegedi Z, Rojkó L, Szállási Z, Döme B, Pipek O, Moldvay J.

Basic Clin Pharmacol Toxicol. 2018 Jan;122(1):126-132. doi: 10.1111/bcpt.12854. Epub 2017 Aug 24.

PMID:
28730730
16.

Influence of lung CT changes in chronic obstructive pulmonary disease (COPD) on the human lung microbiome.

Engel M, Endesfelder D, Schloter-Hai B, Kublik S, Granitsiotis MS, Boschetto P, Stendardo M, Barta I, Dome B, Deleuze JF, Boland A, Müller-Quernheim J, Prasse A, Welte T, Hohlfeld J, Subramanian D, Parr D, Gut IG, Greulich T, Koczulla AR, Nowinski A, Gorecka D, Singh D, Gupta S, Brightling CE, Hoffmann H, Frankenberger M, Hofer TP, Burggraf D, Heiss-Neumann M, Ziegler-Heitbrock L, Schloter M, Zu Castell W.

PLoS One. 2017 Jul 13;12(7):e0180859. doi: 10.1371/journal.pone.0180859. eCollection 2017.

17.

Trimodality therapy for Pancoast tumors: T4 is not a contraindication to radical surgery.

Waseda R, Klikovits T, Hoda MA, Hoetzenecker K, Bertoglio P, Dieckmann K, Zöchbauer-Müller S, Pirker R, Prosch H, Döme B, Klepetko W.

J Surg Oncol. 2017 Aug;116(2):227-235. doi: 10.1002/jso.24629. Epub 2017 Apr 13.

PMID:
28407246
18.

Evaluating the significance of density, localization, and PD-1/PD-L1 immunopositivity of mononuclear cells in the clinical course of lung adenocarcinoma patients with brain metastasis.

Téglási V, Reiniger L, Fábián K, Pipek O, Csala I, Bagó AG, Várallyai P, Vízkeleti L, Rojkó L, Tímár J, Döme B, Szállási Z, Swanton C, Moldvay J.

Neuro Oncol. 2017 Aug 1;19(8):1058-1067. doi: 10.1093/neuonc/now309.

PMID:
28201746
19.

SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers.

Altenberger C, Heller G, Ziegler B, Tomasich E, Marhold M, Topakian T, Müllauer L, Heffeter P, Lang G, End-Pfützenreuter A, Döme B, Arns BM, Klepetko W, Zielinski CC, Zöchbauer-Müller S.

Mol Cancer. 2017 Jan 5;16(1):1. doi: 10.1186/s12943-016-0568-5.

20.

KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis.

Lohinai Z, Klikovits T, Moldvay J, Ostoros G, Raso E, Timar J, Fabian K, Kovalszky I, Kenessey I, Aigner C, Renyi-Vamos F, Klepetko W, Dome B, Hegedus B.

Sci Rep. 2017 Jan 4;7:39721. doi: 10.1038/srep39721.

21.

Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors.

Torok S, Rezeli M, Kelemen O, Vegvari A, Watanabe K, Sugihara Y, Tisza A, Marton T, Kovacs I, Tovari J, Laszlo V, Helbich TH, Hegedus B, Klikovits T, Hoda MA, Klepetko W, Paku S, Marko-Varga G, Dome B.

Theranostics. 2017 Jan 1;7(2):400-412. doi: 10.7150/thno.16767. eCollection 2017.

22.

The evidence for and against different modes of tumour cell extravasation in the lung: diapedesis, capillary destruction, necroptosis, and endothelialization.

Paku S, Laszlo V, Dezso K, Nagy P, Hoda MA, Klepetko W, Renyi-Vamos F, Timar J, Reynolds AR, Dome B.

J Pathol. 2017 Mar;241(4):441-447. doi: 10.1002/path.4855. Epub 2017 Jan 27.

PMID:
28026875
23.

A comparison of sample preparation strategies for biological tissues and subsequent trace element analysis using LA-ICP-MS.

Bonta M, Török S, Hegedus B, Döme B, Limbeck A.

Anal Bioanal Chem. 2017 Mar;409(7):1805-1814. doi: 10.1007/s00216-016-0124-6. Epub 2016 Dec 14.

24.

Inhibition of the transcriptional repressor complex Bcl-6/BCoR induces endothelial sprouting but does not promote tumor growth.

Buchberger E, Payrhuber D, El Harchi M, Zagrapan B, Scheuba K, Zommer A, Bugyik E, Dome B, Kral JB, Schrottmaier WC, Schabbauer G, Petzelbauer P, Gröger M, Bilban M, Brostjan C.

Oncotarget. 2017 Jan 3;8(1):552-564. doi: 10.18632/oncotarget.13477.

25.

Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.

Bridgeman VL, Vermeulen PB, Foo S, Bilecz A, Daley F, Kostaras E, Nathan MR, Wan E, Frentzas S, Schweiger T, Hegedus B, Hoetzenecker K, Renyi-Vamos F, Kuczynski EA, Vasudev NS, Larkin J, Gore M, Dvorak HF, Paku S, Kerbel RS, Dome B, Reynolds AR.

J Pathol. 2017 Feb;241(3):362-374. doi: 10.1002/path.4845. Epub 2016 Dec 29.

26.

Maternal bonding styles in smokers and non-smokers: a comparative study.

Csala I, Elemery M, Martinovszky F, Dome P, Dome B, Faludi G, Sandor I, Gyorffy Z, Birkas E, Lazary J.

Ann Gen Psychiatry. 2016 Nov 11;15:32. eCollection 2016.

27.

The plasma membrane Ca2+ pump PMCA4b inhibits the migratory and metastatic activity of BRAF mutant melanoma cells.

Hegedũs L, Garay T, Molnár E, Varga K, Bilecz Á, Török S, Padányi R, Pászty K, Wolf M, Grusch M, Kállay E, Döme B, Berger W, Hegedũs B, Enyedi A.

Int J Cancer. 2017 Jun 15;140(12):2758-2770. doi: 10.1002/ijc.30503. Epub 2016 Nov 17.

28.

--LUBAC deficiency perturbs TLR3 signaling to cause immunodeficiency and autoinflammation.

Zinngrebe J, Rieser E, Taraborrelli L, Peltzer N, Hartwig T, Ren H, Kovács I, Endres C, Draber P, Darding M, von Karstedt S, Lemke J, Dome B, Bergmann M, Ferguson BJ, Walczak H.

J Exp Med. 2016 Nov 14;213(12):2671-2689. Epub 2016 Oct 24.

29.

Oncolytic influenza A virus expressing interleukin-15 decreases tumor growth in vivo.

Hock K, Laengle J, Kuznetsova I, Egorov A, Hegedus B, Dome B, Wekerle T, Sachet M, Bergmann M.

Surgery. 2017 Mar;161(3):735-746. doi: 10.1016/j.surg.2016.08.045. Epub 2016 Oct 21.

PMID:
27776794
30.

Claudin-1 Protein Expression Is a Good Prognostic Factor in Non-Small Cell Lung Cancer, but only in Squamous Cell Carcinoma Cases.

Moldvay J, Fábián K, Jäckel M, Németh Z, Bogos K, Furák J, Tiszlavicz L, Fillinger J, Döme B, Schaff Z.

Pathol Oncol Res. 2017 Jan;23(1):151-156. doi: 10.1007/s12253-016-0115-0. Epub 2016 Sep 29.

PMID:
27687058
31.

Significance of Primary Tumor Location and Histology for Brain Metastasis Development and Peritumoral Brain Edema in Lung Cancer.

Fábián K, Gyulai M, Furák J, Várallyay P, Jäckel M, Bogos K, Döme B, Pápay J, Tímár J, Szállási Z, Moldvay J.

Oncology. 2016;91(5):237-242. Epub 2016 Aug 26.

PMID:
27562339
32.

Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.

Hoda MA, Pirker C, Dong Y, Schelch K, Heffeter P, Kryeziu K, van Schoonhoven S, Klikovits T, Laszlo V, Rozsas A, Ozsvar J, Klepetko W, Döme B, Grusch M, Hegedüs B, Berger W.

Mol Cancer Ther. 2016 Oct;15(10):2357-2369. Epub 2016 Aug 10.

33.

Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.

Hoda MA, Dong Y, Rozsas A, Klikovits T, Laszlo V, Ghanim B, Stockhammer P, Ozsvar J, Jakopovic M, Samarzija M, Brcic L, Bendek M, Szirtes I, Reid G, Kirschner MB, Kao SC, Opitz I, Weder W, Frauenfelder T, Nguyen-Kim TD, Aigner C, Klepetko W, van Zandwijk N, Berger W, Dome B, Grusch M, Hegedus B.

Eur J Cancer. 2016 Aug;63:64-73. doi: 10.1016/j.ejca.2016.04.018. Epub 2016 Jun 8.

PMID:
27288871
34.

Emphysema- and airway-dominant COPD phenotypes defined by standardised quantitative computed tomography.

Subramanian DR, Gupta S, Burggraf D, Vom Silberberg SJ, Heimbeck I, Heiss-Neumann MS, Haeussinger K, Newby C, Hargadon B, Raj V, Singh D, Kolsum U, Hofer TP, Al-Shair K, Luetzen N, Prasse A, Müller-Quernheim J, Benea G, Leprotti S, Boschetto P, Gorecka D, Nowinski A, Oniszh K, Castell WZ, Hagen M, Barta I, Döme B, Strausz J, Greulich T, Vogelmeier C, Koczulla AR, Gut I, Hohlfeld J, Welte T, Lavae-Mokhtari M, Ziegler-Heitbrock L, Brightling C, Parr DG.

Eur Respir J. 2016 Jul;48(1):92-103. doi: 10.1183/13993003.01878-2015. Epub 2016 May 26.

35.

Lung transplantation in patients with incidental early stage lung cancer-institutional experience of a high volume center.

Klikovits T, Lambers C, Ghanim B, Dome B, Murakoezy G, Zöchbauer-Müller S, Waseda R, Aigner C, Lang G, Taghavi S, Klepetko W, Jaksch P, Hoda MA.

Clin Transplant. 2016 Aug;30(8):912-7. doi: 10.1111/ctr.12764. Epub 2016 Jun 16.

PMID:
27220108
36.

213P: Epithelial tumors of the thymus: Prognostic factors and multidisciplinary treatment.

Ghimessy AK, Kelemen Á, Török K, Gyugos M, Döme B.

J Thorac Oncol. 2016 Apr;11(4 Suppl):S149. doi: 10.1016/S1556-0864(16)30320-3. Epub 2016 Apr 15. No abstract available.

37.

Alterations of tumor microenvironment by carbon monoxide impedes lung cancer growth.

Nemeth Z, Csizmadia E, Vikstrom L, Li M, Bisht K, Feizi A, Otterbein S, Zuckerbraun B, Costa DB, Pandolfi PP, Fillinger J, Döme B, Otterbein LE, Wegiel B.

Oncotarget. 2016 Apr 26;7(17):23919-32. doi: 10.18632/oncotarget.8081.

38.

High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma.

Hoda MA, Rozsas A, Lang E, Klikovits T, Lohinai Z, Torok S, Berta J, Bendek M, Berger W, Hegedus B, Klepetko W, Renyi-Vamos F, Grusch M, Dome B, Laszlo V.

Oncotarget. 2016 Mar 22;7(12):13388-99. doi: 10.18632/oncotarget.7796.

39.

Mechanisms of vascularization in murine models of primary and metastatic tumor growth.

Bugyik E, Renyi-Vamos F, Szabo V, Dezso K, Ecker N, Rokusz A, Nagy P, Dome B, Paku S.

Chin J Cancer. 2016 Feb 12;35:19. doi: 10.1186/s40880-016-0083-5. Review.

40.

Differences in the Epidemiology of Rare EGFR Mutations in Different Populations.

Lohinai Z, Ostoros G, Moldvay J, Dome B, Hegedus B.

J Thorac Oncol. 2016 Jan;11(1):e19-20. doi: 10.1016/j.jtho.2015.09.003. No abstract available.

41.

From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC).

Lohinai Z, Dome P, Szilagyi Z, Ostoros G, Moldvay J, Hegedus B, Dome B, Weiss GJ.

PLoS One. 2016 Jan 6;11(1):e0144797. doi: 10.1371/journal.pone.0144797. eCollection 2016.

42.

[Role of tumour cell invasion/migration in the vascularisation of experimental lung metastases].

Szabó V, Bugyik E, Dezsõ K, Tóvári J, Döme B, Paku S.

Magy Onkol. 2015 Dec;59(4):319-23. Epub 2015 Oct 10. Hungarian.

43.

[Excerpts from the collaborative lung cancer research program of Semmelweis University, the National Institute of Oncology and Korányi Institute of TB and Pulmonology (2010-2015)].

Hegedûs B, Moldvay J, Berta J, Lohinai Z, Rózsás A, Cserepes MT, Fábián K, Ostoros G, Tóvári J, Rényi-Vámos F, Tímár J, Döme B.

Magy Onkol. 2015 Dec;59(4):282-5. Epub 2015 Nov 21. Hungarian.

44.

Heme oxygenase-1 in macrophages controls prostate cancer progression.

Nemeth Z, Li M, Csizmadia E, Döme B, Johansson M, Persson JL, Seth P, Otterbein L, Wegiel B.

Oncotarget. 2015 Oct 20;6(32):33675-88. doi: 10.18632/oncotarget.5284.

45.

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.

Kirschner MB, Pulford E, Hoda MA, Rozsas A, Griggs K, Cheng YY, Edelman JJ, Kao SC, Hyland R, Dong Y, László V, Klikovits T, Vallely MP, Grusch M, Hegedus B, Dome B, Klepetko W, van Zandwijk N, Klebe S, Reid G.

Br J Cancer. 2015 Sep 15;113(6):963-9. doi: 10.1038/bjc.2015.286. Epub 2015 Aug 11.

46.

Reply to Rare Versus Artifactual EGFR Mutations.

Lohinai Z, Ostoros G, Moldvay J, Dome B, Hegedus B.

J Thorac Oncol. 2015 Aug;10(8):e80-1. doi: 10.1097/JTO.0000000000000591. No abstract available.

47.

Drug compound characterization by mass spectrometry imaging in cancer tissue.

Kwon HJ, Kim Y, Sugihara Y, Baldetorp B, Welinder C, Watanabe K, Nishimura T, Malm J, Török S, Döme B, Végvári Á, Gustavsson L, Fehniger TE, Marko-Varga G.

Arch Pharm Res. 2015 Sep;38(9):1718-27. doi: 10.1007/s12272-015-0627-2. Epub 2015 Jul 23. Review.

PMID:
26198812
48.

Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.

Laszlo V, Hoda MA, Garay T, Pirker C, Ghanim B, Klikovits T, Dong YW, Rozsas A, Kenessey I, Szirtes I, Grusch M, Jakopovic M, Samarzija M, Brcic L, Kern I, Rozman A, Popper H, Zöchbauer-Müller S, Heller G, Altenberger C, Ziegler B, Klepetko W, Berger W, Dome B, Hegedus B.

J Pathol. 2015 Oct;237(2):203-14. doi: 10.1002/path.4567. Epub 2015 Jul 14.

PMID:
26011651
49.

A protein deep sequencing evaluation of metastatic melanoma tissues.

Welinder C, Pawłowski K, Sugihara Y, Yakovleva M, Jönsson G, Ingvar C, Lundgren L, Baldetorp B, Olsson H, Rezeli M, Jansson B, Laurell T, Fehniger T, Döme B, Malm J, Wieslander E, Nishimura T, Marko-Varga G.

PLoS One. 2015 Apr 13;10(4):e0123661. doi: 10.1371/journal.pone.0123661. eCollection 2015.

50.

Stromal expression of heat-shock protein 27 is associated with worse clinical outcome in patients with colorectal cancer lung metastases.

Schweiger T, Nikolowsky C, Starlinger P, Traxler D, Zimmermann M, Birner P, Hegedüs B, Dome B, Bergmann M, Mildner M, Klepetko W, Hoetzenecker K, Ankersmit HJ.

PLoS One. 2015 Mar 20;10(3):e0120724. doi: 10.1371/journal.pone.0120724. eCollection 2015.

Supplemental Content

Support Center